Abstract
Biologics have become an increasingly important but also expensive part of the global medicinal cabinet. Generics of this class of drug, termed biosimilars, can relieve the financial burden on healthcare systems and improve patient accessibility. This mini-review covers the evolving international regulatory legislation for biosimilars, challenges for biosimilar development and expected developments.
| Original language | English |
|---|---|
| Pages (from-to) | 77-83 |
| Number of pages | 7 |
| Journal | Journal and Proceedings of the Royal Society of New South Wales |
| Volume | 147 |
| Issue number | 451-452 |
| Publication status | Published - 2014 |
| Externally published | Yes |
Keywords
- Biologics
- Biosimilars
- Regulatory guidelines
- Safety